Formycon And Bio-Thera Kick Off Trials For Keytruda Rivals

Firms Line Up Pembrolizumab Biosimilars As Bio-Thera Files Ustekinumab In EU And US

 
• By Dave Wallace

Two more firms, Formycon and Bio-Thera, have revealed the latest updates in their efforts to bring a Keytruda biosimilar to market.

Vial of pembrolilzumab
Two more companies have begun trials for pembrolizumab • Source: Shutterstock

More from Biosimilars

More from Products